UT Southwestern Medical Center at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
UT Southwestern Medical Center brings 35 presentations to ObesityWeek 2026 in National Harbor. Its program centers on obesity medicines, from trials of new GLP-1 drugs such as aleniglipron, retatrutide and berobenatide to real-world studies of GLP-1 use, coverage loss and pregnancy outcomes. It also shows how fasting and exercise drive ghrelin release through sympathetic nerve circuits.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
UT Southwestern Medical Center Dallas, TX | |
Academic medical center in Dallas with a medical school, research labs and hospitals. | Session Fri Nov 13 1:00pm–6:15pm Pediatric Obesity: Comprehensive Care and Practical Strategies for Today's Clinician - Day 1 Practical course for clinicians on pediatric obesity care, combining nutrition, behavior therapy and newer drugs, with case simulations and workflow strategies. Clinical obesity care and professional practiceObesity pharmacotherapy and drug developmentPediatric and adolescent obesityNutrition, diet and food Talk Fri Nov 13 2:00pm–2:45pm Medical Assessment of Obesity Clinical obesity care and professional practiceObesity pharmacotherapy and drug developmentPediatric and adolescent obesityNutrition, diet and food Talk Sat Nov 14 11:15am–11:30am Talk Sat Nov 14 2:00pm–2:15pm Talk Sat Nov 14 6:25pm–6:35pm Award for Distinguished Mentorship Recipient Metabolism and integrative physiologyNeuroscience of appetite and eatingInterventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practicePolicy and public health Poster Sat Nov 14 7:30pm–8:30pm Pregnancy Outcomes Associated with MASLD Among Women with Overweight or Obesity Chronic disease and obesity complications Poster Sat Nov 14 7:30pm–8:30pm STEP UP of Semaglutide 7.2 mg from 2.4 mg in Obesity: Predicted Benefit and Clinical Confirmation Chronic disease and obesity complicationsObesity pharmacotherapy and drug development Poster Sat Nov 14 7:30pm–8:30pm Sympathetic Circuitry and Transcriptional Remodeling of Gastric Ghrelin Cells During Fasting Neuroscience of appetite and eatingObesity pharmacotherapy and drug development Talk Sun Nov 15 7:30am–8:30am The Obesity Treatment Journey: Evaluating Burden, Discontinuation, and Outcomes Uses a patient case and real-world data to examine why patients stop obesity treatment, what follows, and care changes that keep people on therapy. Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practicePolicy and public healthNutrition, diet and foodChronic disease and obesity complicationsNeuroscience of appetite and eatingObesity pharmacotherapy and drug development Session Sun Nov 15 9:30am–10:30am Talk Sun Nov 15 10:30am–10:45am Poster Sun Nov 15 2:30pm–3:30pm Rationale and Design of the KaiNETIC-3 Trial of Ribupatide in People With Obesity and No Diabetes Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Berobenatide (MET-097, PF-08653944) in Adults With Overweight/Obesity and Type 2 Diabetes: VESPER-2 Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Dose-Ranging Effects of Aleniglipron, an Oral Small-Molecule GLP-1RA for Obesity: The ACCESS Trials Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Dose-Ranging Phase 2 Trial of CX11, a Small-Molecule GLP-1 RA, in People with Overweight and Obesity Interventional and clinical studiesObesity pharmacotherapy and drug development Session Sun Nov 15 3:30pm–4:30pm Talk Sun Nov 15 4:20pm–4:30pm Talk Sun Nov 15 5:00pm–6:30pm Talk Sun Nov 15 5:20pm–5:25pm Lipid Mobilization Establishes Metabolic Tolerance to Infection Metabolism and integrative physiologyInterventional and clinical studiesClinical obesity care and professional practiceObesity pharmacotherapy and drug developmentChronic disease and obesity complicationsNutrition, diet and food Talk Sun Nov 15 6:30pm–9:00pm Obesity in Focus: Today's Evidence. Tomorrow's Possibilities. Speakers cover what has changed in obesity guidelines, evidence behind approved obesity drugs, and the biology of amylin and new amylin analog data. Interventional and clinical studiesClinical obesity care and professional practiceNutrition, diet and foodObesity pharmacotherapy and drug development Talk Mon Nov 16 11:45am–12:45pm Glucagon’s Role in Metabolic Regulation and Why It Matters Covers how glucagon and the liver regulate glucose and fat metabolism and why this matters in obesity and related heart, kidney and metabolic diseases. Metabolism and integrative physiologyChronic disease and obesity complications Session Mon Nov 16 12:00pm–1:00pm TOS Population Science and Public Health Section Meeting (TOS members only) Section members hear talks from early-career top abstract award winners, get section updates and learn about open leadership positions. Population health and epidemiologyPolicy and public health Poster Mon Nov 16 2:30pm–3:30pm Demographic Variation in GLP‑1 RA Use and Persistence in Adults With Obesity: Real-World Evidence Population health and epidemiology Poster Mon Nov 16 2:30pm–3:30pm GLP-1 Receptor Agonist Use and Pregnancy Outcomes Among Women With Obesity Chronic disease and obesity complications Poster Mon Nov 16 2:30pm–3:30pm Poster Mon Nov 16 2:30pm–3:30pm “I Have to Get Sicker to Get Medication”: Patient Experiences Following GLP-1 RA Coverage Loss Policy and public health Poster Mon Nov 16 2:30pm–3:30pm Health Consequences Following Employer Withdrawal of GLP-1 Receptor Agonist Coverage for Obesity Policy and public health Poster Mon Nov 16 2:30pm–3:30pm Exploring Associations Between Household Food Insecurity and Adolescent Cardiovascular Health Risks Pediatric and adolescent obesityPopulation health and epidemiology Poster Mon Nov 16 2:30pm–3:30pm Accumulated Obesity Treatment History Predicts Current GLP-1RA Use Among Adults with BMI ≥50 kg/m² Clinical obesity care and professional practice Poster Mon Nov 16 2:30pm–3:30pm Associations of Central Adiposity and Anthropometric Measures with Uterine Cancer Among U.S. Women Population health and epidemiologyNutrition, diet and food Poster Mon Nov 16 2:30pm–3:30pm Phthalate and Plasticizer Metabolites and Metabolic Syndrome in U.S. Adolescents and Young Adults Pediatric and adolescent obesityPopulation health and epidemiology Poster Mon Nov 16 2:30pm–3:30pm Updated Waist Circumference Percentiles Among U.S. Children and Adolescents, NHANES 2011-2023 Pediatric and adolescent obesityPopulation health and epidemiology Poster Mon Nov 16 2:30pm–3:30pm Perceived Barriers to Bariatric Surgery Among Adults With Prior GLP-1RA Use and BMI ≥50 kg/m² Population health and epidemiology Talk Mon Nov 16 6:15pm–6:30pm Session Tue Nov 17 11:00am–12:30pm Brainy Brunch Trivia Throwdown Closing brunch where tables team up for trivia drawn from across the meeting, mixing attendees from different tracks to swap takeaways. |
Find decision makers at UT Southwestern Medical Center
Tell us what you sell and we’ll find the people at UT Southwestern Medical Center most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction